Impact of Disease Characteristics on 1L Treatment Decisions in EGFRm NSCLC

Disease Characteristics Influencing Treatment Selection

Main Discussion Topics:

• Impact of specific disease features on treatment decisions
• Role of CNS metastases in guiding therapy selection
• Identification of high-risk features that benefit from treatment escalation

Key Points for Physicians:

• Both FLAURA2 and MARIPOSA demonstrated superior CNS efficacy compared with osimertinib monotherapy
• High-risk features benefiting from combination therapy include TP53/RB alterations, high disease burden, liver metastases, and CNS involvement
• Hazard ratios show particularly strong benefit for patients with brain metastases (HR, 0.47 in FLAURA2; HR, 0.67 for overall survival in MARIPOSA)

Notable Insights:

Combination therapy approaches may allow some patients with brain metastases to avoid radiation therapy.

Clinical Significance:

Patients with CNS disease and other high-risk features represent a subgroup with a particularly strong rationale for intensification of first-line therapy beyond osimertinib monotherapy.